U.S. :
+1-206-701-6702
UK :
+44-020-8133-4027
JAPAN :
+81-50-5539-1737
INDIA :
+91-848-285-0837
Press Release: Antibacterial Drugs Market to Reach US$ 44,063.3 Million by 2027
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Antibacterial drugs are majorly used in treatment and prevention of infectious diseases and are categorized into seven major classes based on their molecular structure namely, aminoglycosides, β-Lactams, tetracyclines, sulfonamides, quinolones, macrolides, and phenicols.
The global antibacterial drugs market is estimated to account for US$ 42,048.3 Mn in terms of value IN 2020 and is expected to reach US$ 44,063.3 Mn by the end of 2027.
Global Antibacterial Drugs Market: Drivers
Increasing prevalence of bacterial infections is expected to propel growth of the global antibacterial drugs market over the forecast period. For instance, according to the study, ‘Prevalence of bacterial vaginosis and associated risk factors in pregnant women receiving antenatal care at the Kumba Health District (KHD), Cameroon’, published in May 2019, the prevalence of bacterial vaginosis was 26.2% in the study population.
Moreover, increasing approval and launch of new antibacterial drugs is also expected to aid in growth of the market. For instance, in November 2019, Shionogi Inc. received the U.S. Food and Drug Administration approval for its Fetroja (cefiderocol), an antibacterial drug for treatment of complicated urinary tract infections in patients 18 years of age or older.
β-lactams held dominant position in the global antibacterial drugs market in 2019, accounting for 59.3% share in terms of value, followed by Quinolones and Macrolides, respectively.
Figure 1. Global Antibacterial Drugs Market Share (%), by Value, by Drug Class, 2019
Global Antibacterial Drugs Market: Restraints
Increasing number of multi-drug resistant bacterial strains is expected to hinder growth of the market. Excessive usage of various antibacterial drugs has led to evolution of various multi-drug resistant bacterial strains such as vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA), extended-spectrum β-lactamase (ESBLs), MDR Escherichia coli, MDR Klebsiella pneumoniae, MDR Acinetobacter baumannii, MDR Pseudomonas aeruginosa, and MDR Enterococcus faecium.
Moreover, failure of current antibiotic discovery model in delivering new agents in order to contain present levels of antibiotic resistance is also expected to limit growth of the market.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2019 | Market Size in 2019: | US$ 41,780.2 Mn |
| Historical Data for: | 2016 to 2019 | Forecast Period: | 2020 to 2027 |
| Forecast Period 2020 to 2027 CAGR: | 0.7% | 2027 Value Projection: | US$ 44,063.3 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered (28): |
Shionogi Inc, Iterum Therapeutics plc, Kyorin Pharmaceutical Co., Ltd., Allecra Therapeutics GmbH, Wockhardt Ltd., Theravance Biopharma, Inc., R-Pharm Group, Entasis Therapeutics, Melinta Therapeutics, Micurx Pharmaceutical Inc., Debiopharm Group, Boston Pharmaceuticals Inc., TenNor Therapeutics, Sichuan Pharmaceutical Co., Ltd., NacuGen Therapeutics Inc., VenatoRx Pharmaceuticals, Inc., Spero Therapeutics, GlaxoSmithKline plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Laboratories, Inc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Global Antibacterial Drugs Market: Opportunities
Pharmaceutical companies have failed to deliver significant number of new antibacterial drugs. In the future, companies need to adopt collaboration and partnership strategies for R&D on new antibacterial drugs.
Moreover, investment in the R&D of previously characterized lead compounds that did not commercialize is also expected to aid in growth of the market. With improved technology and expertise, the failed candidates can be safe and efficacious antibacterial drugs.
The global antibacterial drugs market was valued at US$ 41,780.2 Mn in 2019 and is forecast to reach a value of US$ 44,063.3 Mn by 2027 at a CAGR of 0.7% between 2020 and 2027.
Figure 2. Global Antibacterial Drugs Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027
Market Trends/Key Takeaways
Loss of patent and marketing exclusivity of antibacterial drugs has led to generic drug manufacturers introducing their own version of antibacterial drugs in the market. These off-patent molecules have attracted a large number of manufacturers and today account for a sizeable portion of the global antibacterial drugs market.
R&D in drug-resistant bacteria is expected to propel growth of the global antibacterial drugs market. For instance, in November 2019, researchers from Northeastern University, Boston, U.S., reported development of a new antibiotic darobactin that selectively eliminates Gram-negative pathogens.
Global Antibacterial Drugs Market: Competitive Landscape
Major players operating in the global antibacterial drugs market include Shionogi Inc, Iterum Therapeutics plc, Kyorin Pharmaceutical Co., Ltd., Allecra Therapeutics GmbH, Wockhardt Ltd., Theravance Biopharma, Inc., R-Pharm Group, Entasis Therapeutics, Melinta Therapeutics, Micurx Pharmaceutical Inc., Debiopharm Group, Boston Pharmaceuticals Inc., TenNor Therapeutics, Sichuan Pharmaceutical Co., Ltd., NacuGen Therapeutics Inc., VenatoRx Pharmaceuticals, Inc., Spero Therapeutics, GlaxoSmithKline plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Laboratories, Inc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi.
Global Antibacterial Drugs Market: Key Developments
Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in September 2019, Kyorin Pharmaceutical Co., Ltd. received approval to market the oral quinolone antibacterial drug Lasvic Tablets 75mg, for the treatment of respiratory and ENT infections, from the Ministry of Health, Labor and Welfare, Japan.
Major players in the market are also focused on R&D of new antibacterial drugs. For instance, in October 2018, Iterum Therapeutics plc presented data on sulopenem, its novel oral and IV penem antibiotic at IDWeek 2018 in San Francisco, U.S.
Antibacterial drugs play a major role in advanced healthcare, as they are majorly used in treatment and prevention of infectious diseases. Antibacterial drugs act by destroying or inhibiting microbial growth. Antibacterial drugs are used in treatment of infection caused by various bacteria such as Escherichia coli, Klebsiella pneumonia, and others. Moreover, increasing incidences of infectious diseases such as tuberculosis, hepatitis B, leprosy, typhoid, malaria, HIV/AIDS and others is expected to drive the market growth. According to the World Health Organization (WHO) November 2018 factsheet, an estimated 219 million people were diagnosed by malaria in 2017, in 19 countries.
Restraints of the Global Antibacterial Drugs Market
Major factors hampering the growth of the antibacterial drugs market during the forecast period constitutes of increasing number of multi-drug resistant bacterial strains, and failure to advance robust therapies in the pipeline phases.
Key features of the study:
Detailed Segmentation
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 35 market data tables and 26 figures on “Antibacterial Drugs Market – Global forecast to 2027.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Sales Office (U.S.) : Coherent Market Insights Pvt Ltd, 1001 4th Ave,
#3200 Seattle, WA 98154, U.S.
Asia Pacific Intelligence Center (India) : Coherent Market Insights Pvt Ltd, 203, 2nd Floor,
Bremen Business Center, Aundh, Pune,
Maharashtra 411007, India.
UK :
+44-020-8133-4027
JAPAN :
+81-50-5539-1737
This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection
US :
INDIA :
UK :
JAPAN :
Contact Us
